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IntroductIon
The liver has a tolerogenic immunological landscape in keep-
ing with its constant exposure to microbial products and 
food-derived antigens draining from the gut via the por-
tal vein. Intrahepatic T cell responses must be regulated to 
protect this vital organ from excessive immunopathology 
(Protzer et al., 2012). The unique liver niche is frequently 
exploited by hepatotropic infections and tumors, which ac-
count for a huge burden of global mortality. For example, 
chronic hepatitis B (CHB) kills ∼780,000 people annually, 
and hepatocellular carcinoma (HCC) is the second leading 
cause of cancer deaths (GBD 2013 Mortality and Causes of 
Death Collaborators, 2015). There are currently intensive 
efforts to develop immunotherapeutic approaches for these 
liver diseases, stimulated by recent successes with other ma-
lignancies. The rationale for this goal is supported by the fact 
that most adults infected with hepatitis B virus (HBV) resolve 
the infection naturally, maintaining the virus under lifelong 
immune control. There is therefore an urgent need to char-
acterize the features of T cells able to overcome tolerance in 
the liver to provide effective long-term immunosurveillance.
Little is known about the composition of the T cell 
compartment in the healthy human liver because of limita-
tions in tissue access. It is critical to understand whether the 
liver contains specialized local populations capable of acting 
as sentinels against infection that cannot be studied by sam-
pling blood. Recent studies in both mice and humans have 
revealed that a large proportion of memory CD8 T cells in 
nonlymphoid tissues are resident, representing functionally 
distinct populations of T cells poised to provide local pro-
tection against invading pathogens. Tissue-resident memory T 
cells (TRM) cannot reenter the circulation and are intimately 
adapted to individual organs by microenvironmental cues 
(Sathaliyawala et al., 2013; Schenkel and Masopust, 2014; Ii-
jima and Iwasaki, 2015; Park and Kupper, 2015; Steinert et al., 
2015; Thome and Farber, 2015; Fernandez-Ruiz et al., 2016; 
Hombrink et al., 2016; Mueller and Mackay, 2016). Elegant 
intravital imaging in mouse models has visualized CD8 T 
cells patrolling the extensive, narrow-lumenal, sinusoidal vas-
culature and surveying hepatocytes (through fenestra in the 
endothelium) for infection with HBV or malaria sporozoites 
(Guidotti et al., 2015; Fernandez-Ruiz et al., 2016). Limited 
data indicate that HBV-specific CD8 T cells are enriched in 
human livers (Maini et al., 2000; Fisicaro et al., 2010), but 
no studies have addressed whether these responses are simply 
an accumulation of the small populations that can be sam-
the liver provides a tolerogenic immune niche exploited by several highly prevalent pathogens as well as by primary and meta­
static tumors. We have sampled healthy and hepatitis B virus (HBV)–infected human livers to probe for a subset of t cells 
specialized to overcome local constraints and mediate immunity. We characterize a population of t­betloEomesloBlimp­1hiHobitlo 
t cells found within the intrahepatic but not the circulating memory cd8 t cell pool expressing liver­homing/retention markers 
(cd69+cd103+ cXcr6+cXcr3+). these tissue­resident memory t cells (trM) are preferentially expanded in patients with partial 
immune control of HBV infection and can remain in the liver after the resolution of infection, including compartmentalized 
responses against epitopes within all major HBV proteins. Sequential IL­15 or antigen exposure followed by tGFβ induces 
liver­adapted trM, including their signature high expression of exhaustion markers Pd­1 and cd39. We suggest that these 
inhibitory molecules, together with paradoxically robust, rapid, cell­autonomous IL­2 and IFnγ production, equip liver cd8 trM 
to survive while exerting local noncytolytic hepatic immunosurveillance.
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pled in blood or whether they contain a discrete fraction 
sequestered in the liver.
In this study, we have analyzed T cells freshly isolated 
from the livers of a large number of healthy and HBV-infected 
donors, including unprecedented intrahepatic sampling 
from those with low viral loads or long-term resolution of 
HBV infection. We define the signature of a TRM popula-
tion within the human liver that cannot be sampled in the 
periphery, which is strikingly expanded in HBV infection, 
contains virus-specific responses and is associated with HBV 
control. The features that instruct these memory CD8 T cells 
to be retained, survive, and exert rapid noncytolytic antiviral 
cytokine production in the liver, in addition to the signals 
required for their induction, provide important insights for 
therapeutic vaccination and immunotherapy of CHB, HCC, 
and other hepatic diseases.
rESuLtS and dIScuSSIon
a population of cd8 t cells expressing the tissue retention 
signals cd69/cd103/cXcr6 is sequestered in 
the healthy human liver
We performed an extensive study of the healthy human in-
trahepatic CD8 T cell compartment, with sixteen-parameter 
flow cytometric analysis (Fig. S1 a) of freshly isolated leuko-
cytes from 54 liver samples (healthy liver pretransplantation 
biopsies or perfusates and resected healthy liver margins of 
colorectal metastases) compared with healthy donor PBMCs. 
The naive CD8 T cell compartment (CD27+CD45RA+) was 
significantly contracted in all liver samples compared with the 
periphery (P < 0.0001) and replaced with an expanded pool 
of memory subsets (CD27+CD45RA−, CD27−CD45RA− 
and CD27−CD45RA+; Fig. 1 a).
To examine frequencies of CD8 T cells with the poten-
tial to be retained in the human liver, we analyzed their expres-
sion of CD69, a negative regulator of sphingosine 1 phosphate 
receptor 1 (S1PR1)–mediated T cell egress (Skon et al., 2013). 
Another bona fide tissue residency marker is the α chain of 
the integrin αEβ7, CD103 (Mackay et al., 2013; Sathaliyawala 
et al., 2013); the combination of CD103 with CD69 defined 
a population of cells within the intrahepatic CD8 T cell pool 
(Fig. 1 b) that was restricted to the CD45RA− memory com-
partment (Fig. 1 c). CD69+CD103+ comprised a mean 11.4% 
of the intrahepatic memory pool, whereas they were virtually 
undetectable (mean <1%) in the periphery (Fig. 1 d), suggest-
ing they were tissue-resident (henceforth referred to as TRM). 
In contrast, the CD69−CD103− subset likely represented non-
resident liver-infiltrating CD8 T cells (more frequent in blood 
than livers; Fig. S1 b); this is in line with the substantial pop-
ulation of memory T cells able to recirculate from the mouse 
liver (Steinert et al., 2015). The CD69+CD103− subset was 
also greatly enriched in the liver and, like the CD69+CD103+ 
TRM, did not express CCR7 or CD62L but was not excluded 
from the periphery (Fig. S1, c and d).
In further support of CD69+CD103+ TRM being 
a distinct subset, their transcription factor profile 
(T-betloEomesloBlimp-1hiHobitlo; Fig. S1 e) was different from 
other liver and peripheral memory CD8 T cells. Their pro-
file was similar to TRM from other tissue sites (Hombrink et 
al., 2016; Mackay et al., 2016) with the exception of Hobit, 
which showed a converse pattern to mouse TRM (Mackay 
et al., 2016) but analogous to human tonsillar T cells (Vieira 
Braga et al., 2015). Because liver TRM could not be discrim-
inated by a simple single or dual profile, we performed mul-
tidimensional analysis using t-distributed stochastic neighbor 
embedding (tSNE), confirming that their transcription fac-
tors contributed to CD69+CD103+ TRM, forming a discrete 
population (separated from the CD69−CD103− by the inter-
mediate CD69+CD103− intrahepatic memory CD8 T cells; 
Fig. 1 e). Not only did CD69 and CD103 coexpression de-
fine discrete clusters of phenotypically similar cells on the 
tSNE map, but the transcription factors also showed clear 
clusters that overlapped with residency subsets (Fig. 1 e). The 
CD69+CD103− subset was more heterogeneous in their tran-
scription factor expression, suggesting they were composed 
Figure 1. Liver­resident memory cd8 t cells are present in the human liver but not in blood. (a) Frequencies of CD8 T cell differentiation/memory 
subsets (CD27+CD45RA+; CD27+CD45RA−; CD27−CD45RA−; and CD27−CD45RA+) in peripheral blood (n = 40 healthy controls) and intrahepatic samples 
(n = 11 healthy liver tissues; n = 19 healthy margins of resected tissue distant to colorectal carcinoma metastases [CRC margins], and n = 24 perfusates). 
(b) Percent CD69+CD103+ of healthy control peripheral (n = 40) and intrahepatic CD8 T cells (n = 10 healthy liver tissues, n = 20 CRC margins, and n = 27 
perfusates). (c) Intrahepatic CD69+CD103+ CD8 T cells stratified by memory phenotype in healthy livers (n = 47). (d) Percent CD69+CD103+ within mem-
ory (CD45RA−) CD8 in healthy control PBMCs (n = 40) or livers (n = 54). (e) The dimensionality reduction method tSNE analysis was used to generate a 
two-dimensional map of T cells within perfusate samples from healthy livers with regard to their expression of key transcription factors and tissue-residency 
markers. tSNE was performed on the expression data for the markers CD69, CD103, Blimp-1, Eomes, and T-bet as measured by FACS on all CD3+CD8+C-
D45RA− events concatenated from four perfusates. Manual gating was used to identify CD69+CD103+ (black), CD69+CD103− (red), and CD69−CD103− T cells 
(blue) as shown in the bottom left corner. These gated populations were then plotted on to the total tSNE map. (f and g) Representative immunofluores-
cence staining of frozen liver sections: hepatocytes surrounding a vessel stained with cytokeratin (green) and e-cadherin (red; f), and another vessel stained 
with CD8 (green) and CD103 (red; g). Arrows in g denote cells coexpressing CD8 and CD103 in situ. (h–l) Representative examples and summary data from 
circulating (white), intrahepatic CD45RA−CD69−CD103− (gray), and intrahepatic CD45RA−CD69+CD103+ (black) memory CD8 T cells from healthy donors for 
CXCR6 (%; n = 24) and CXCR3 (MFI; n = 21; h), CD98 (MFI; n = 12) and CD14 (%; n = 20; i), perforin (MFI; n = 16) and granzyme B (MFI; n = 16; j), HLA-DR 
(%; n = 21; k), and IFNγ and IL-2 intracellular cytokine production (4 h anti-CD3 and anti-CD28; n = 15; l). Error bars indicate means ± SEM; *, P < 0.05; **, 
P < 0.01; ***, P < 0.001; ****, P < 0.0001; p-values were determined via MAN OVA (a); Kruskal-Wallis test (ANO VA) with a Dunn’s post hoc test for pairwise 
multiple comparisons (b, c, h, i, j, k, and l); and Mann-Whitney t test (d).
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of more than one discrete subset (Fig. S1 e). Further analysis 
revealed that this subset contained a large fraction of muco-
sal invariant T cells and a smaller proportion of γδ T cells, 
whereas CD69+CD103+ TRM were largely conventional T 
cells (Fig. S1 f). We therefore focused our study primarily on 
comparing CD69+CD103+ and CD69−CD103− liver subsets. 
However, future work could take advantage of the recently 
reported additional markers for tissue-residency of T cells in 
the mouse liver (McNamara et al., 2017) and human skin 
(Cheuk et al., 2017) to assess whether they can discriminate a 
population within the CD69+CD103− liver subset restricted 
to conventional αβ T cells and excluded from the circulation.
The expression of CD103 on TRM contributes to their 
retention in barrier tissues by allowing them to bind to epithe-
lial cells expressing e-cadherin, the ligand for αEβ7 (Mackay 
et al., 2013). Healthy liver sections showed strong widespread 
e-cadherin staining of hepatocytes (Fig. 1 f), highlighting the 
potential relevance of this ligand for any liver TRM within the 
parenchyma. Our findings suggest that CD103-expressing 
lymphocytes were frequently localized within the vasculature 
(because they were isolated from perfusates as well as tissue 
homogenates and visualized in vessels; Figs. 1  g and S1  g), 
from where they could potentially interact with e-cadherin–
expressing hepatocytes through sinusoidal fenestra. This find-
ing is analogous to the large fraction of TRM noted to be in 
the marginated pool of mouse livers (Steinert et al., 2015).
Studies in mice have demonstrated the importance of 
CXCR6-dependent retention of memory CD8 T cells in the 
mouse liver for malaria protection, and human sinusoidal cells 
and hepatocytes can express the relevant ligand CXCL16 
(Heydtmann et al., 2005; Wehr et al., 2013; Tse et al., 2014). 
TRM (CD69+CD103+) and CD69+CD103− CD8 T cells were 
markedly enriched for expression of the liver homing/reten-
tion receptor CXCR6 compared with CD69−CD103− in-
trahepatic or peripheral memory CD8 T cells (Figs. 1 h and 
S1  h). We recently found that CXCR6 also marks a large 
subset of NK cells resident in the human liver (Stegmann 
et al., 2016). Human hepatic endothelium has also been 
shown to express CXCR3 ligands (Curbishley et al., 2005), 
and CXCR3 is critical for directing TRM to virally infected 
mouse skin. Liver CD8 TRM expressed much higher levels of 
CXCR3 than other intrahepatic and peripheral lymphocytes 
(Figs. 1 h and S1 h), suggesting that this chemokine receptor 
may also play a role in their homing and/or retention.
Hepatic cd8 trM express high autocrine 
IL­2 and low granzyme B
Having identified a large population of CD8 T cells with a 
TRM phenotype sequestered in the healthy human liver, we 
next investigated whether they were imprinted by their local 
milieu. To probe for evidence of the shaping of liver TRM by 
their nutrient microenvironment, we assessed their expres-
sion of system-L amino acid transporters marked by CD98. 
The liver TRM fraction was selectively enriched for CD98 
expression (Figs. 1 i and S1 i), which we have shown to be 
up-regulated in response to arginine deprivation (Pallett et 
al., 2015). Intriguingly, a proportion of liver TRM expressed 
CD14, the coreceptor for TLR-4–mediated LPS recognition, 
that was barely expressed on CD69−CD103− or circulating 
memory CD8 T cells (Figs. 1 i and S1 i). CD14 has previously 
been reported to be induced on T cells by TCR engage-
ment and cytokine stimulation, rendering them responsive 
to LPS, with the production of high concentrations of IFNγ 
(Komai-Koma et al., 2009). Further work is required to inves-
tigate whether CD14 on liver TRM can regulate responsive-
ness to the large amounts of LPS that they would encounter 
from the portal blood supply.
To assess the functional adaptations of liver CD8 
TRM, we stained them directly ex vivo for cytotoxic me-
diators. Although they expressed more perforin than their 
CD69−CD103− intrahepatic and circulating counterparts, 
hepatic CD8 TRM had markedly reduced levels of the serine 
protease granzyme B (Fig. 1  j) and less granzyme A and K 
(Fig. S1 j). This suggested the possibility of down-regulated 
capacity for immediate cytotoxicity, limiting T cell–medi-
ated immunopathology in the healthy liver. Despite their 
selectively impaired granzyme expression, CD8 TRM had 
increased levels of ex vivo activation (HLA-DR) compared 
with the CD69−CD103− intrahepatic or circulating memory 
CD8 T cells (Fig. 1 k). Upon short-term polyclonal stimu-
lation to assess their immediate effector potential, liver CD8 
TRM were able to produce equivalent amounts of IFNγ to 
the CD69−CD103− fraction. Most strikingly, a much larger 
proportion of liver CD8 TRM produced IL-2 compared with 
their CD69−CD103− and circulating counterparts. A mean of 
23.5% (maximum 65.2%) of intrahepatic CD8 TRM produced 
IL-2 after just 4 h of stimulation, whereas there was negligi-
ble production by circulating memory CD8 T cells (Fig. 1 l). 
This unusually high IL-2 production is likely to be criti-
cal to the protective potential of hepatic CD8 TRM as it has 
been demonstrated that CD8 T cells need to make their own 
cell-autonomous supplies of IL-2 to drive adequate IFNγ 
production and persistence of memory responses to patho-
gens (Zimmerli et al., 2005; Feau et al., 2011). The capacity of 
CD8 T cells to produce and consume their own IL-2 may be 
particularly relevant for the maintenance of effective memory 
responses in peripheral tissues like the liver, where CD4 T cell 
frequencies are low, and priming of CD4 T cell responses is 
suboptimal (Zimmerli et al., 2005; Crispe, 2014).
Liver trM are a tightly regulated population that expand in 
hepatotropic viral infection
To examine the relevance of TRM to local immune defense in 
the liver, we investigated their in vivo response to persistent 
infection with the highly prevalent hepatotropic virus HBV. 
We obtained paired blood and surplus diagnostic liver biopsy 
samples from 33 patients with treatment-naive CHB; in every 
case, CD8 TRM were detectable in the liver and remained ex-
cluded from the blood (Fig. 2 a), as in healthy controls. Intra-
hepatic CD8 TRM were highly enriched in the setting of HBV 
o
n
 June 26, 2017
D
ow
nloaded from
 
Published May 19, 2017
1571JEM Vol. 214, No. 6
Figure 2. cd8 trM expand in patients controlling HBV infection. (a and b) Frequencies of CD69+CD103+ as percentages of the CD8 T cell mem-
ory (CD45RA−) pool in paired blood and liver biopsies from patients with chronic HBV infection (n = 33; a) and biopsy/resection tissue from healthy 
(n = 54) or HBV-infected (n = 35) livers (b). (c) Percent intrahepatic CD8 T cells within live singlet lymphocytes and stratified by differentiation/memory 
subsets (defined in Fig. 1). (d–f) PD-1 expression (percentage and MFI) on circulating (white), intrahepatic CD45RA−CD69−CD103− (gray), and intrahe-
patic CD45RA−CD69+CD103+ (black) memory CD8 T cells isolated from healthy controls (n = 26; d), patients with CHB (n = 13; e), and comparing in-
trahepatic CD45RA−CD69+CD103+ CD8 T cells from healthy controls and CHB (f). (g) CD39 expression (percentage) on circulating (white), intrahepatic 
CD45RA−CD69−CD103− (gray), and intrahepatic CD45RA−CD69+CD103+ (black) memory CD8 T cells isolated from healthy controls (n = 25) or CHB (n = 18). 
(h) Representative example of PD-1 expression on CD39−/CD39+ CD45RA−CD69+CD103+ CD8 T cells. (i) Representative immunohistochemical staining of 
PD-L1 (brown) and CD8 (gray) using a paraffin-embedded liver section. Arrow denotes PD-L1 staining on a cell localized in the liver sinusoids. (j–l) Ki67 (%; 
n = 10; j), CD57 (%; n = 5; k) and granzyme B (MFI; n = 9; l) expression on circulating (white), intrahepatic CD45RA−CD69−CD103− (gray), and intrahepatic 
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infection compared with healthy livers, with a mean threefold 
increase in frequency, accounting for up to 68.5% of all in-
trahepatic memory CD8 T cells (Fig. 2 b). This reflected an 
increased conversion to a resident phenotype within the pool 
of intrahepatic CD8 T cells rather than selective expansion of 
the TRM subset because there was no significant change in the 
overall proportion of CD8 T cells or memory subsets in an 
HBV-infected liver relative to a healthy liver (Fig. 2 c).
The liver contains a large proportion of CD8 T cells 
compared with the blood (mean 72% versus 31% of total 
CD3 T cells in this cohort); these must be tightly regulated 
to prevent immunopathological damage. The coinhibitory 
receptor PD-1 is known to play a central role in liver tol-
erance in mouse models (Iwai et al., 2003; Isogawa et al., 
2005) and in constraining intrahepatic antiviral responses 
to HBV (Fisicaro et al., 2010), but little is known about its 
expression on T cell subsets within the healthy human liver. 
The percentage of memory CD8 T cells expressing PD-1 
and the level of its expression (mean fluorescence intensity; 
MFI) showed a stepwise increase from blood to nonresident 
to resident populations in healthy livers (Fig. 2 d). PD-1 was 
significantly higher on TRM within HBV-infected livers than 
on nonresident or circulating memory CD8 T cell counter-
parts in these patients (Fig.  2  e) and compared with levels 
on TRM in healthy controls (Fig. 2 f). Virtually all CD8 TRM 
in HBV-infected livers expressed PD-1 (mean 92.4%), and 
their level of PD-1 expression (MFI) was more than twofold 
higher than on nonresident CD8 T cells (Fig. 2 e) or TRM in 
healthy livers (Fig. 2 f).
The ectonucleotidase CD39 was also expressed on 
a much higher percentage of CD8 TRM in healthy and 
HBV-infected livers compared with nonresident intrahepatic 
and circulating memory CD8 T cells (Fig.  2 g). CD39 has 
recently been found to identify terminally exhausted CD8 T 
cells expressing the highest level of PD-1 within virus-specific 
populations circulating in patients with hepatitis C and in 
mice with lymphocytic choriomeningitis virus (Gupta et al., 
2015). In line with this finding, CD39 marked CD8 TRM with 
the highest PD-1 expression in the liver (Fig. 2 h). Our data 
reveal that CD39 expression is a feature of a large proportion 
of liver-resident CD8 T cells. The high-level expression of the 
exhaustion markers PD-1 and CD39 on liver CD8 TRM was 
at odds with their capacity to mount immediate strong cyto-
kine responses (e.g., IL-2–producing cells expressed equiv-
alently high PD-1 and CD39 to the rest of TRM; Fig. S2 a). 
Their efficient production of cell-autonomous IL-2 may be 
instrumental in instructing this “poised” state. In support of 
this, IL-2 production by mouse CD8 T cells allows them to 
overcome PD-L1–mediated inhibition by liver sinusoidal en-
dothelial cells (Schurich et al., 2010).
PD-L1 can be expressed by several liver-resident cell 
types and further up-regulated in inflammatory settings such 
as viral hepatitis (Iwai et al., 2003; Mühlbauer et al., 2006). In 
support of this, we observed strong PD-L1 staining on sinu-
soidal populations with morphology suggestive of Kupffer 
cells, in close proximity to CD8 T cells in CHB (Fig. 2  i). 
Recent work using genetic knockdown of PD-1 on mouse 
CD8 T cells has pointed to a central role for this coinhibitory 
receptor in preserving T cells in the face of chronic antigenic 
stimulation by preventing excessive proliferation and terminal 
senescence (Odorizzi et al., 2015). Congruent with CD8 TRM 
expressing high PD-1 in an environment enriched for PD-L1 
expression, direct ex vivo staining confirmed constraints on 
their proliferation (Ki67; Fig. 2 j), senescence (CD57; Figs. 2 k 
and S2 b), and cytotoxicity (granzyme B; Fig. 2 l).
Sequential exposure to IL­15 and tGFβ and/or  
tcr engagement induces the Pd­1hi liver­resident  
cd8 t cell phenotype
We next investigated the signals required to impose or main-
tain the liver residency phenotype on CD8 T cells. PBMCs 
devoid of CD8 TRM were treated with cytokines relevant to 
the liver and/or the promotion of tissue residency (IL-15, 
TGFβ, IL-33, IL-7, IL-12, TNF, CXCL16, and IL-6). Of the 
cytokines tested, IL-15 was able to induce CD69 expres-
sion on peripheral CD8 T cells in a dose-dependent manner 
(Fig. 3 a) as well as up-regulating the chemokine receptors 
CXCR6 and CXCR3 (Fig. 3 b) that we previously noted 
on ex vivo liver TRM. IL-15 is constitutively produced in 
the liver (Golden-Mason et al., 2004), is capable of induc-
ing antigen-independent T cell differentiation (Alves et al., 
2003), and drives bystander T cell activation in viral infec-
tions such as HBV (Sandalova et al., 2010). None of the cy-
tokines alone, including IL-15 or TGFβ, were able to induce 
significant expression of CD103, required to tether CD8 T 
cells to e-cadherin for their retention in the liver (Fig. 3 c). 
However, sequential exposure to IL-15 followed by TGFβ ef-
ficiently induced de novo CD8 TRM expressing both CD69 
and CD103 at a similar frequency to that found in the healthy 
liver (Fig.  3  d). Reversal of the two-step cytokine signal 
(TGFβ followed by IL-15) did not induce TRM (Fig.  3  d), 
whereas IL-15 followed by IL-33 (equivalent to TGFβ in its 
capacity to induce tissue residency in mice; Mackay et al., 
2013) was only able to induce marginal expansion of human 
CD69+CD103+ CD8 T cells (Fig. 3 e).
The induction of tissue residency can also be instructed 
by local antigen in mouse viral infection or vaccination (Fer-
nandez-Ruiz et al., 2016; Khan et al., 2016; Muschaweckh et 
al., 2016). To test this possibility, we substituted IL-15 with 
a TCR-dependent signal initially by cross-linking CD3. 
CD45RA−CD69+CD103+ (black) on memory CD8 T cells from patients with CHB. Error bars indicate means ± SEM; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, 
P < 0.0001; p-values were determined via Wilcoxon Signed-rank t test (a); Mann-Whitney t test (b, c, and f); MAN OVA (c); and Kruskal-Wallis test (ANO VA) 
with a Dunn’s post hoc test for pairwise multiple comparisons (c, d, e, g, j, k, and l).
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TCR stimulation, similar to IL-15, showed a potent capacity 
to recapitulate the liver CD8 TRM phenotype using human 
PBMCs, with induction of a population expressing CD69 
and CD103 and up-regulation of CXCR6 and CXCR3 
(Fig. 3, f and g). The TCR-mediated induction of CD8 T cells 
expressing CD69 and CD103 was further enhanced by sub-
sequent stimulation with TGFβ in a dose-dependent manner 
(Fig. 3  f). TRM could be induced from antigen-experienced 
(CD45RA−) and naive (CD27+CD45RA+) peripheral CD8 
T cells (more readily from the former; Fig. S2 c), suggesting 
that both fractions may be amenable to therapeutic attempts 
to enhance tissue residency. To examine whether recognition 
of HBV-infected hepatocytes could contribute to the in-
creased expansion of liver CD8 TRM we had observed in pa-
tients with CHB, we used overlapping peptides spanning the 
HBV core region (or peptides representing control epitopes 
from cytomegalovirus/Epstein–Barr virus/influenza; CEF) as 
the TCR stimulus. HBV and other viral peptide-responding 
(IFNγ+) CD8 T cells up-regulated both CD69 and CD103 
(Fig. 3 h), indicating that antigen recognition can substitute 
for cytokines for in situ induction of the liver TRM phenotype.
We went on to examine CD8 TRM induced from 
PBMCs (by sequential IL-15/TGFβ or TCR engagement/
TGFβ) for expression of other markers we had found to 
characterize TRM extracted from human livers. We found that 
CD8 T cells with an in vitro “induced residency” phenotype 
also developed a CD14+CD39+PD-1hi and BlimphiEomeslo 
profile (Fig. 3 i) comparable to the phenotypic and transcrip-
tional adaptations characterizing liver-resident populations. In 
addition, they up-regulated Notch (Fig. 3 i), which drives a 
program of human lung residency (Hombrink et al., 2016), 
underscoring some striking similarities between TRM in dif-
ferent human organs (Hombrink et al., 2016; Wong et al., 
2016). Our data delineate signals relevant to the liver envi-
ronment that are capable of recapitulating the phenotype of 
liver-resident CD8 T cells. We show that TGFβ, a prototypic 
liver cytokine, plays a key role in inducing CD103 expression 
to retain CD8 T cells that have received an initial homing 
signal from the bystander proinflammatory cytokine IL-15. 
Kupffer cells, specialized macrophages that line hepatic vas-
culature, constitute a major source of TGFβ and IL-15 as well 
as the ligands for CXCR6 and PD-1 and are therefore likely 
candidates to imprint infiltrating T cells with signals driving 
the combination of features allowing them to reside and sur-
vive in the liver microenvironment. IL-15 and TGFβ are to-
gether capable of inducing a population of resident T cells 
while also imposing a highly constrained (PD-1hiCD39+) 
phenotype to facilitate their long-term survival in the face 
of antigenic challenge. TCR engagement, for example by in 
situ recognition of viral epitopes, can substitute for these cy-
tokine signals or can synergize with TGFβ to further promote 
T cell residency in the human liver, likely contributing to the 
increased TRM observed in HBV infection. Our data suggest 
that a TCR signal or the bystander cytokine IL-15 should 
precede exposure to TGFβ for optimal induction of CD69/
CD103 coexpressing TRM.
Liver­resident cd8 t cells containing IL­2high multispecific 
HBV­specific t cells are associated with viral control
We next took advantage of the heterogeneity of disease out-
come after infection with HBV to probe the protective po-
tential of TRM in the human liver. We observed that the HBV 
viral load showed a stepwise decrease as the frequency of in-
trahepatic CD8 TRM increased, with the highest frequency 
found in patients with well-controlled infection (≤2,000 IU/
ml; Figs. 4 a and S3 a), whereas there was no correlation with 
levels of surface antigen (hepatitis B surface antigen; HBsAg), 
liver inflammation (alanine transaminase) or hepatitis B ‘e’ 
antigen (HBeAg; Fig. S3 a). Congruent with their associa-
tion with viral control, the TRM pool contained HBV-specific 
CD8 T cells identified by staining with a combined panel of 
HLA-A2–peptide dextramers (in a subset of four HLA-A2+ 
individuals; Fig. 4 b). Around 40% of the dextramer-stained 
HBV-specific CD8 T cells in the liver were classical TRM 
(CD45RA−CD69+CD103+), whereas another large fraction 
(>40%) were within the CD69+CD103− subset (Fig.  4  b) 
that is also largely compartmentalized within the liver. Thus, 
a major proportion of HBV-specific CD8 T cells are likely 
resident in the liver, implying that the small subset sampled in 
the periphery is not representative of the whole population.
Figure 3. Sequential exposure to IL­15 or antigen and tGFβ induces cd8 “residency” in vitro. (a and b) CD69 expression (%; n = 27; a) and CXCR6 
(%; n = 17) or CXCR3 (%; n = 12; b) expressing peripheral CD8 T cells after 3 d culture in the presence of rhIL-15 at indicated doses (red; n = 11). (c and d) 
Coexpression of CD69 and CD103 on peripheral CD8 T cells (“induced” CD69+CD103+ CD8 T cells; n = 11) after either rhIL-15 alone (red) or rhTGFβ alone 
(blue; c) at the indicated doses for 6 d, two-step sequential cytokine exposure with 3 d rhIL-15 followed by a further 3 d rhTGFβ (red) at concentrations of 
both cytokines indicated or vice versa (blue; n = 20; d) or two-step sequential cytokine exposure with 3 d rhIL-15 followed by 3 d rhIL-33 at concentrations 
of both cytokines indicated (n = 11; e). (f) Frequency of induced CD69+CD103+ CD8 T cells after two-step culture with 3 d 0.25 µg/ml immobilized anti-CD3 
followed by 3 d ± addition of rhTGFβ at concentrations indicted (n = 12). (g) Expression of CXCR6 (%; n = 12) and CXCR3 (%; n = 12) on peripheral CD8 T 
cells after 6 d 0.25 µg/ml immobilized anti-CD3 (n = 10). (h) Frequency of induced CD69+CD103+ within the global or peptide-specific (HBV or CEF) CD8 T 
cells after culture with either 1 µg/ml of overlapping peptides spanning the core region of HBV genotype D or 0.5 µg/ml CEF (peptide pool against CEF) for 
7 d (n = 12). (i) Expression of CD14 (%; n = 17), CD39 (%; n = 20), PD-1 (MFI; n = 17), Blimp-1 (MFI; n = 12), Eomes (MFI; n = 6), and Notch (MFI; n = 6) on 
CD69−CD103− CD8+ (white) and CD69+CD103+ (“induced resident;” black) CD8 T cells after sequential exposure to 3 d of 50 ng/ml rhIL-15 followed by 3 d 
of 50 ng/ml rhTGFβ. All figures show summary data from at least four independent experiments. Error bars indicate means ± SEM; *, P < 0.05; **, P < 0.01; 
***, P < 0.001; ****, P < 0.0001; p-values were determined via a Kruskal-Wallis test (ANO VA) with a Dunn’s post hoc test for pairwise multiple comparisons 
(a, c, d, e, and f) or a Wilcoxon Signed-rank t test (b, g, h, and i).
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To assess the effector potential and multispecific-
ity of intrahepatic virus-specific CD8 T cells, we obtained 
perfusates from HBV-infected livers; these yielded suffi-
cient lymphocytes to allow overnight stimulation with in-
dividual pools of peptides spanning different HBV proteins 
(which did not alter their CD69/CD103 phenotype; Fig. S3 
b), before intracellular cytokine staining. This gave the first 
ex vivo insight into the multispecificity of the intrahepatic 
HBV-specific response, revealing the presence of CD8 T cells 
responding to each of the HBV protein pools, with a partic-
ularly large response to the envelope peptides (example in 
Fig. 4 c). This contrasts with the much lower frequency of 
circulating HBV-specific CD8 T cells, and in particular of en-
velope-specific CD8 T cells, found in previous peptide stim-
ulation studies using PBMCs (Bertoletti and Ferrari, 2016). 
Consistent with extensive compartmentalization of the 
HBV-specific response at the site of infection, the majority 
of intrahepatic cytokine-producing CD8 T cells had either 
a CD69+CD103− or a CD69+CD103+ phenotype (Fig. 4, c 
and d), congruent with ex vivo and cytokine-negative CD8 
(Fig. S3 b). Intrahepatic CD8 T cells with a TRM phenotype 
were able to produce IFNγ and TNF upon recognition of 
HBV epitopes thathave been shown to mediate noncyto-
lytic clearance of HBV from infected hepatocytes. Whereas 
IL-2–producing HBV-specific CD8 T cells are virtually 
undetectable in PBMC studies of CHB (Boni et al., 2012), 
IL-2 production was strikingly enriched in the HBV-specific 
TRM compartment (Fig. 4 d). Comparison of intrahepatic re-
sponses against HBV and control (CEF) peptides revealed that 
some intrahepatic CEF responses also had a CD69+CD103+ 
phenotype, but this liver residency phenotype was increased 
within HBV-specific CD8 (Fig. 4 e).
To further investigate our postulate that IL-2 produc-
tion is a key feature of liver TRM allowing their long-term 
survival and local antiviral efficacy, we took advantage of 
unique access to intrahepatic lymphocytes (IHLs) from two 
donors who had previously achieved immune resolution of 
their HBV infection. Such donors (HBsAg−, anti-HBsAb+/
anti-HBcAb+, and HBV DNA undetectable), who have pre-
viously only been studied in the periphery, provide a model 
for “functional cure” of HBV because traces of virus remain 
under active control by persistent T cell responses and can 
reactivate during immunosuppressive therapy (Rehermann 
et al., 1996). Investigation of these “gold-standard” responses 
at the site of immune control showed the persistence of vi-
rus-specific T cell responses in the liver after disease resolu-
tion; these were detectable directly ex vivo (stained with a 
panel of HLA-A2/peptide multimers; Fig. 4 f) and directed 
against multiple HBV proteins, particularly envelope (after 
overnight peptide stimulation; Fig. 4 g). Around 10% of these 
intrahepatic IFNγ+ responses were CD69+CD103+, and the 
majority of the remainder were CD69+CD103− (similar to 
ex vivo and IFNγ− CD8; Fig. S3 b), suggesting that they may 
be able to reside in the liver to prevent reactivation of re-
sidual intrahepatic HBV. Responses against all peptide pools 
produced IL-2, and these were disproportionately enriched 
within the CD69+CD103+ TRM fraction (Fig. 4 g). This sup-
ported our hypothesis that CD8 cell-autonomous IL-2 allows 
liver-resident T cells to survive and maintain functionality. 
Such maintenance of long-lived antiviral T cells within tissues 
has been noted in mice after resolution of vesicular stomatitis 
virus or listeria infection (Masopust et al., 2001). 
In summary, we show for the first time that global and 
virus-specific CD8 TRM compartmentalized within the vascu-
lature of the healthy human liver expand and persist in patients 
partially or fully controlling hepatotropic viral infection. These 
TRM are enriched for liver-homing chemokine receptors and 
exhibit other adaptations to the liver niche that can be recapit-
ulated using sequential stimulation of PBMCs with IL-15 or 
TCR engagement and TGFβ. They are distinguished by the 
combination of high cell-autonomous IL-2 and PD-1 and 
are poised to mount immediate noncytolytic antiviral effector 
functions. Our findings have several important implications for 
current intensive efforts to develop therapeutic vaccines and 
other immunotherapies for HBV and HCC. Our data under-
score the need to sample the liver to assess immunotherapeutic 
responses by these local, specialized, sentinel T cells, which are 
not represented in the blood. This is exemplified by a recent 
study showing that intravenous administration of a malaria vac-
cine enhanced its efficacy, in association with the expansion 
of pathogen-specific CD8 T cells in the liver (Ishizuka et al., 
2016). We provide a blueprint for the induction of T cells able 
Figure 4. Liver cd8 trM include virus­specific cd8 and are associated with HBV control. (a) Frequencies of CD45RA−CD69+CD103+ CD8 T cells in 
HBV-infected liver biopsies stratified by viral load (IU/ml; ≤2,000, n = 10; 2 × 103 − 2 × 105, n = 15; >2 × 105, n = 8; all treatment naive) compared with 
healthy livers (n = 54). (b–d) Proportion of HBV-specific CD8 T cells in CHB expressing residency markers CD103 and CD69, identified by ex vivo staining 
with a panel of HLA-A2–HBV peptide dextramers (example plots for blood and an HBV+ resection liver; summary data n = four livers; one resection, three 
biopsies; b) or after stimulation of IHL for 16 h with 10 µg/ml of overlapping peptides spanning core, polymerase, or envelope regions (using an HBsAg+ HBV 
perfusate; c) and after 16-h stimulation with core (HBV genotype D) alone and intracellular cytokine staining for IFNγ, TNF, and IL-2 (n = 7; d). (e) Propor-
tion of CEF–specific (n = 10; four margins, six biopsies) and HBV-specific (n = 8; one resection, one perfusate, six biopsies) IFNγ CD8 responses expressing 
a CD45RA−CD69+CD103+ phenotype. (f) Detection of CD8 T cells according to CD69 and CD103 expression within ex vivo HLA-A2–HBV dextramer (dex.) 
panel-binding cells in an HLA-A2+ perfusate sample from an individual with HBsAg-resolved HBV infection. (g) IHLs from an HLA-A2 perfusate from an in-
dividual with HBsAg-resolved HBV infection were stimulated with 10 µg/ml of overlapping peptides spanning core, envelope, or polymerase regions of HBV 
genotype D for 16 h followed by intracellular cytokine staining for IFNγ and IL-2 and assessment of residency markers on cytokine-positive populations. 
Error bars indicate means ± SEM; *, P < 0.05; **, P < 0.01; ****, P < 0.0001; p-values were determined by a Kruskal-Wallis test (ANO VA) with a Dunn’s post 
hoc test for pairwise multiple comparisons (a) or Wilcoxon Signed-rank t test (e).
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to reside in the liver, well positioned to maintain hepatic im-
munosurveillance and exert rapid front-line pathogen defense.
MatErIaLS and MEtHodS
Ethical approval
This study was approved by the local National Health Ser-
vices Research Ethics Committees for either The Royal Lon-
don Hospital or The Royal Free Hospital and complies with 
the Declaration of Helsinki. All healthy controls and patients 
gave written informed consent before inclusion.
Samples
Resected liver tissue from the healthy margins of 19 colorectal 
metastatic tumor resections were obtained through the Tissue 
Access for Patient Benefit scheme at The Royal Free Hospital 
(approved by the University College London–Royal Free Hos-
pital BioBank Ethical Review Committee; Research Ethics 
Committee reference number 11/WA/0077). Additional liver 
samples were obtained as follows: perfusion liquid (perfusate) 
from 24 healthy livers used for solid-organ transplantation; tis-
sue from three healthy livers deemed unsuitable for transplan-
tation (e.g., vascular abnormalities, warm ischemic time >30 
min, or identification of a tumor elsewhere in the donor); and 
biopsies taken from eight healthy livers before transplantation 
(RIP COLT clinical trial; Research Ethics Committee refer-
ence number 11/H0720/4; trial number 8191; trial registered 
at clinicaltrials.gov: NCT00796588). For comparison, 40 pe-
ripheral blood samples from healthy control individuals were 
included within the study (approved by the South East Coast 
Research Ethics Committee; Research Ethics Committee ref-
erence number 11/LO/0421; IRAS project number, 43993). 
All healthy control participants used within the study were anti- 
HBV, anti–hepatitis C, and anti-HIV antibody negative.
For HBV+ liver tissue, we used clinical biopsy tissue 
deemed surplus to diagnostic requirements from 33 patients 
with treatment-naive CHB, none of whom had end-stage 
cirrhosis (obtained with paired blood samples from the same 
individuals), from The Royal London Hospital (approved by 
East London and The City Research Ethics Committee; Re-
search Ethics Committee reference number P/01/023). We 
also used two perfusates from HBV-exposed donor livers 
(one HBsAg−, anti-HBsAb+, anti-HBcAb+ resolved, and one 
HBsAg+ healthy carrier; RIP COLT trial) and two margins of 
resected HCCs from The Royal Free Hospital (Tissue Access 
for Patient Benefit). Participants with chronic HBV infection 
were anti–hepatitis C and anti-HIV antibody negative, and all 
were treatment naive (apart from the two from whom resec-
tions were obtained) and were stratified by HBV viral load 
(IU/ml; determined by real-time PCR), serum HBsAg titer 
(IU/ml; determined by Architect; Abbott Diagnostics), pres-
ence of HBeAg, and serum alanine transaminase (IU/liter).
PBMc and IHL isolation
PBMCs were isolated from heparinized blood by density 
centrifugation using Ficoll-Hypaque Plus (GE Healthcare). 
For CD8 TRM quantification, all samples were used imme-
diately where possible. Samples not used immediately were 
frozen in 10% DMSO (Sigma-Aldrich) in FBS (Sigma-Al-
drich) and were stored in accordance with the Human Tissue 
Act. IHLs from biopsy tissue of either healthy livers or livers 
from patients with CHB were isolated by mechanical dis-
ruption using cell scrapers without further processing (debris 
removed by passing single cell suspension through 70-µM cell 
strainers from BD). With larger explant tissues, sections were 
cut into small pieces and incubated for 30 min at 37°C in 
0.01% collagenase IV (Invitrogen) and 0.001% DNase I (Sig-
ma-Aldrich). After enzymatic digestion, mechanical digestion 
was performed using a GentleMACS (Miltenyi Biotec). After 
full digestion, debris was removed as before, and parenchymal 
cells were removed by centrifugation on a 30% Percoll gra-
dient (GE Healthcare). Finally, IHLs were isolated by density 
centrifugation using Ficoll-Hypaque Plus. When processing 
perfusate samples, perfusion liquid was first concentrated 
by centrifugation. Concentrated cells were resuspended in 
RPMI 1640 (Gibco), and lymphocytes were isolated by den-
sity centrifugation using Ficoll-Hypaque Plus.
Flow cytometry for trM phenotype and function
Multiparametric flow cytometry was used for phenotypic and 
functional analysis of PBMCs and IHLs. Cells were stained 
with a fixable Live/Dead dye (Invitrogen) before incubation 
with saturating concentrations of surface mAbs diluted in 
50% Brilliant violet buffer (BD) and 50% PBS for 30 min 
at 4°C. See also Table S1 for full details regarding antibodies 
used. Cells were fixed and permeabilized for further func-
tional assessment with either Cytofix/Cytoperm (BD) or 
FoxP3 Buffer Set (BD) according to the manufacturer’s in-
structions. Saturated concentrations of mAbs for 30 min at 
4°C were diluted in 0.1% saponin (Sigma-Aldrich) for the 
detection of intracellular proteins or in 1× PBS for the de-
tection of intranuclear proteins. All samples were acquired on 
either an LSR II or X20 flow cytometer (BD) and analyzed 
using FlowJo (Tree Star).
Induction of trM phenotype
PBMCs from healthy controls at 3 × 105 cells/well were in-
cubated with either (i) 5, 10, or 50 ng/ml of recombinant 
human (rh) IL-15, TGFβ, IL-7, IL-33, CXCL16, IL-6, or 
IL-12 (R&D Systems) or combinations of these for cytokine 
induction; (ii) 0.25 µg/ml immobilized anti-CD3 (eBiosci-
ence) for 24 h and then rested for a further 48 h before in-
creasing doses of rhTGFβ or 5 d resting; or (iii) with 1 µg/
ml overlapping peptide (pool of 15-mer peptides overlap-
ping by 10 residues) spanning the core (JPT Technologies), 
envelope, and polymerase (Massachusetts General Hospital 
Peptide Synthesis Facility) proteins of the HBV genotype 
Dor 5 µg/ml HLA-A– and HLA-B–restricted peptide pools 
spanning the immunodominant proteins of CEF (JPT Tech-
nologies) for 7 d. All experiments were done in complete 
RPMI (cRPMI; RPMI-1640 containing 10% FBS, 100 U/
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ml penicillin/streptomycin, 1× nonessential amino acids, 1× 
essential amino acids, and β-mercaptoethanol; Invitrogen) and 
cultured in the presence of 20 IU/ml rhIL-2 (Miltenyi Bio-
tec) for 3/6/7 d at 37°C. After culture, cells were stained for 
CD8+ TRM frequency, surface phenotype, and transcription 
factor profiling by flow cytometry as in the prior section. In 
some experiments, naive (CD27+CD45RA+) and memory 
(CD45RA−) CD8 T cells were FACS sorted from five dif-
ferent PBMC donors before TRM induction with cytokine or 
TCR engagement with immobilized anti-CD3.
Immunohistochemistry/Immunofluorescence
For immunohistochemistry, healthy margin or diseased liver 
samples from patients with CHB were obtained from surgery, 
fixed in neutral buffered formalin solution, and embedded 
in paraffin. 5-µm sections were mounted and rehydrated in 
xylene, descending alcohol concentrations, and distilled water. 
For antigen retrieval, slides were microwaved for 8 min in 
10 mmol/liter Tris and 1 mmol/liter EDTA buffer, pH 9, 
and equilibrated in PBS. Endogenous peroxidase activity was 
quenched by immersion in 1% H2O2/MeOH for 10 min. 
Nonspecific antibody binding was blocked with 5% nonfat 
skimmed milk in PBS for 30 min, and slides were incubated 
in primary antibody diluted in 1% BSA in PBS overnight 
at 4°C. After washing in PBS, slides were immersed for 30 
min in the corresponding ImmPRE SS HRP Polymer De-
tection solution (Vector Laboratories). Antibody complexes 
were visualized by brief incubation in chromagen DAB/SG 
HRP substrate (Vector Laboratories). Slides were rinsed in 
distilled water, counterstained in hematoxylin, dehydrated 
via an ascending alcohol gradient and xylene, and mounted 
in a mixture of distyrene, plasticizer, and xylene. For immu-
nofluorescence, frozen healthy liver margins from surgery or 
core needle–biopsy specimens obtained from CHB patients 
for diagnostic purposes were embedded in optimum cutting 
temperature compound (RA Lamb) and frozen on dry ice. 
5-µm sections were cut, mounted, fixed in acetone for 10 
min and then were air dried and washed in PBS. Nonspecific 
antibody binding was blocked with 2.5% normal horse serum 
(Vector Laboratories) for 30 min before incubation with pri-
mary antibody diluted in 1% BSA in PBS overnight at 4°C. 
After washing with PBS, slides were incubated in the appro-
priate secondary antibody diluted in 1% BSA in PBS for 1 h 
at room temperature and then were washed and mounted in 
Vectashield mounting medium with DAPI (Vector Labora-
tories). Sections were imaged using a high-resolution digital 
Axio Scan.Z1 slide scanner and associated Zen software (ZEI 
SS). Primary and secondary antibodies used were as follows: 
mouse anti–human e-cadherin (HECD-1; Abcam), anti–
human cytokeratin-FITC (CK3-6H5; Miltenyi Biotech), rat 
anti–human CD8 (YTC141.1HL; AbD Serotec), mouse anti–
human CD69 (FN50; BioLegend), mouse anti–human CD8 
(C8/144B; Dako), rabbit anti–human integrin α E (CD103; 
EPR4166(2); Abcam), rabbit anti–human PD-L1 (E1L3N; 
Cell Signaling Technology), anti–mouse IgG1 Alexa Fluor 
568 (Thermo Fisher Scientific), anti–rat IgG Alexa Fluor 488 
(Thermo Fisher Scientific), anti–mouse IgG1 Alexa Fluor 
488 (Thermo Fisher Scientific), and anti–rabbit IgG Alexa 
Fluor 594 (Thermo Fisher Scientific).
dextramer staining for the 
identification of virus­specific trM
HBV-specific HLA-A2 dextramers (Immudex) of the fol-
lowing specificities were used: core 18–27 (FLP SDF FPFV), 
envelope 183–191 (FLL TRI LTI), envelope 335–342 (WLS 
LLV PFV), envelope 348–357 (GLS PTV WLSV), polymerase 
455–463 (GLS RYV ARL), and polymerase 502–510 (KLH 
LYS HPI). Cells were stained with dextramers at 37°C in 
1× PBS, washed twice in cRPMI, and left to rest for 1 h in 
cRPMI before further mAb staining as described in the Flow 
cytometry for TRM phenotype and function section (Fig. 4, 
b and f). During analysis, stringent gating criteria were ap-
plied with doublet, dead, and CD19+ cell exclusion to mini-
mize nonspecific binding contamination. A dextramer loaded 
with an irrelevant peptide was used in parallel to control 
for nonspecific binding.
Functional assessment of cd8 trM
To assess the production of cytokines by CD8 TRM, 106 
IHLs were stimulated with either 0.5 µg/ml immobilized 
anti-CD3 and 5 µg/ml anti-CD28 (eBioscience); 10 µg/ml 
overlapping peptides (pool of 15-mer peptides overlapping 
by 10 residues) spanning the core, envelope, and polymerase 
proteins of HBV genotype D; or 5 µg/ml HLA-A– and 
HLA-B–restricted peptide pools spanning the immunodomi-
nant proteins of CEF. For HLA-A2+ donors, IHLs were stim-
ulated with 10 µM HBV-derived HLA-A2 restricted peptides 
(FLP SDF FPSV [core]; FLL TRI LTI, WLS LLV PFV, LLV PFV 
QWFV, and GLS PTV WLSV [envelope]; and GLS RYV ARL 
and KLH LYS HPI [polymerase]; ProImmune). All functional 
experiments were performed in the presence of 1 µg/ml 
brefeldin-A (Sigma-Aldrich) for 4 h or 16 h at 37°C. Specific 
responses were detected by intracellular cytokine staining 
as described in the Flow cytometry for TRM phenotype and 
function section (Figs. 1 and 4).
Statistical analysis
Statistical analyses were performed in either Prism (Graph-
Pad Software) or R version 3.2.4 using appropriate methods 
as indicated in the legends (Mann-Whitney t test, Wilcoxon 
Signed-rank t Test, Kruskal-Wallis test [ANO VA] with a 
Dunn’s post hoc test for pairwise multiple comparisons be-
tween each group, Spearman’s Rank Order Correlation, or 
multivariate ANO VA [MAN OVA]), with significant differ-
ences marked on all figures. Specifically, the MAN OVA was 
used when more than one dependent variable of interest was 
considered simultaneously to more than one independent 
variable of interest. Where appropriate, the Bonferroni cor-
rection method for multiple testing was used. All tests were 
performed as two-tailed tests, and for all tests, significance 
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levels were defined as *, P < 0.05; **, P < 0.01; ***, P < 
0.001; and ****, P < 0.0001.
tSnE analysis
tSNE analysis was performed on flow cytometry data from 
four perfusates stained on cytobank as described in the 
Flow cytometry for TRM phenotype and function section 
(Kotecha et al., 2010) using default parameters (Iterations, 
1,000; perplexity, 30; and θ, 0.5). tSNE was applied to ex-
pression data for CD69, CD103, Blimp-1, Eomes, and T-bet 
for all live CD3+CD8+CD45RA− events after concatenat-
ing four donor perfusates.
online supplemental material
Fig. S1 shows a profile of liver-resident memory CD8 T 
cell in the healthy human liver. Fig. S2 shows the function 
and phenotype of TRM. Fig. S3 shows the phenotypic and 
transcription profiling of CD45RA−CD69+CD103− and 
CD69+CD103+ intrahepatic CD8 T cells. Table S1 is a list of 
monoclonal antibody details.
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